{"protocolSection":{"identificationModule":{"nctId":"NCT01107353","orgStudyIdInfo":{"id":"IMIP-C75-PVFS-1"},"organization":{"fullName":"West-Ward Pharmaceutical","class":"INDUSTRY"},"briefTitle":"Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions","officialTitle":"A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions"},"statusModule":{"statusVerifiedDate":"2018-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-08"},"primaryCompletionDateStruct":{"date":"2008-09","type":"ACTUAL"},"completionDateStruct":{"date":"2008-09","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-19","studyFirstSubmitQcDate":"2010-04-19","studyFirstPostDateStruct":{"date":"2010-04-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-11-26","resultsFirstSubmitQcDate":"2013-11-26","resultsFirstPostDateStruct":{"date":"2014-01-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-01-19","lastUpdatePostDateStruct":{"date":"2018-02-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Roxane Laboratories","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The objective of this study was to prove the bioequivalence of Imipramine Pamoate 75 mg Capsules under fasting conditions"},"conditionsModule":{"conditions":["Depression"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":39,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"First Imipramine Pamoate, then Tofranil-PM","type":"ACTIVE_COMPARATOR","description":"First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)","interventionNames":["Drug: Imipramine Pamoate"]},{"label":"First Tofranil PM, then imipramine pamoate","type":"ACTIVE_COMPARATOR","description":"First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)","interventionNames":["Drug: Imipramine Pamoate"]}],"interventions":[{"type":"DRUG","name":"Imipramine Pamoate","description":"75 mg capsule","armGroupLabels":["First Imipramine Pamoate, then Tofranil-PM","First Tofranil PM, then imipramine pamoate"],"otherNames":["TOFRANIL-PM"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Bioequivalence Determined by Statistical Comparison Cmax","description":"Blood samples were collected pre-dose and at intervals over 120 hours after each dose","timeFrame":"33 Days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening\n\nExclusion Criteria:\n\n* Positive test for HIV, Hepatitis B, or Hepatitis C.\n* Treatment with known enzyme altering drugs.\n* History of allergic or adverse response to imipramine pamoate or any comparable or similar product.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Soran Hong, M.D.","affiliation":"Novum Pharmaceutical Research Services","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Novum Pharmaceutical Research Services","city":"Houston","state":"Texas","zip":"77042-4712","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"First Imipramine Pamoate, Then Tofranil-PM","description":"First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"},{"id":"FG001","title":"First Tofranil PM, Then Imipramine Pamoate","description":"First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Positive Drug Screen","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Normal healthy volunteers","groups":[{"id":"BG000","title":"First Imipramine Pamoate, Then Tofranil-PM","description":"First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"},{"id":"BG001","title":"First Tofranil PM, Then Imipramine Pamoate","description":"First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.41","spread":"7.65"},{"groupId":"BG001","value":"28.41","spread":"7.65"},{"groupId":"BG002","value":"28.41","spread":"7.65"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"27"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Bioequivalence Determined by Statistical Comparison Cmax","description":"Blood samples were collected pre-dose and at intervals over 120 hours after each dose","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"33 Days","groups":[{"id":"OG000","title":"First Imipramine Pamoate, Then Tofranil-PM","description":"First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"},{"id":"OG001","title":"First Tofranil PM, Then Imipramine Pamoate","description":"First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"7.48"},{"groupId":"OG001","value":"11.3","spread":"7.03"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"33 days","eventGroups":[{"id":"EG000","title":"First Imipramine Pamoate, Then Tofranil-PM","description":"First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule","seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":0,"otherNumAtRisk":20},{"id":"EG001","title":"First Tofranil PM, Then Imipramine Pamoate","description":"First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)\n\nImipramine Pamoate: 75 mg capsule","seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":0,"otherNumAtRisk":20}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Anton (Tony) Amann, PhD., Executive Director, DRAMA","organization":"Roxane Laboratories, Inc.","email":"tony.amann@boehringer-ingelheim.com","phone":"614-272-4785"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003863","term":"Depression"}],"ancestors":[{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"}]},"interventionBrowseModule":{"meshes":[{"id":"D007099","term":"Imipramine"}],"ancestors":[{"id":"D003984","term":"Dibenzazepines"},{"id":"D006575","term":"Heterocyclic Compounds, 3-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}